Oncolytic virus intravenous delivery system based on bimetal nanodots and preparation method and application of oncolytic virus intravenous delivery system

By constructing a bimetallic nanodot-oncolytic virus intravenous delivery system, the tumor-killing ability and visualization evaluation of oncolytic viruses were enhanced, overcoming the limitations of drug delivery methods in oncolytic virus therapy and achieving efficient tumor treatment and imaging effects.

CN118987254AActive Publication Date: 2024-11-22SHENYANG PHARMA UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411120977.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

Current oncolytic virus therapies are mostly administered via intratumoral injection, which has limited efficacy and lacks a visual evaluation system. Enhancing the tumor-killing ability of oncolytic viruses and establishing an evaluation system have become urgent problems to be solved.

Method used

A bimetallic nanodot-oncolytic virus intravenous delivery system was designed. By covalently linking oncolytic adenoviruses, the bimetallic nanodots enhance the tumor-killing ability and enable MRI, shielding viral surface antigens to avoid immune clearance and promoting long-term viral circulation in the body.

Benefits of technology

This method enables highly efficient intravenous injection of oncolytic viruses to enhance tumor-killing capabilities, provides visualization evaluation via magnetic resonance imaging, enhances viral penetration and retention at tumor sites, and improves the efficacy and safety of tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987254A_ABST
    Figure CN118987254A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug delivery carriers, and particularly relates to an oncolytic virus vein delivery system based on bimetallic nanodots, a preparation method thereof and application of the oncolytic virus vein delivery system in tumor immunotherapy. According to the invention, oncolytic adenovirus and gadolinium-iron bimetallic nanodots are used as raw materials, and covalent acting force of 4-maleimidobutyric acid-N-succinimide ester is utilized to construct a bimetallic nanodot-adenovirus chimera, so that the oncolytic adenovirus-gadolinium-iron bimetallic nanodots are synthesized. The preparation performance, the cytotoxicity, the action mechanism, the in-vivo anti-tumor effect, the anti-tumor immunity, the anti-tumor recurrence and metastasis effect and the like of the chimera are evaluated. The preparation process is simple, and the prepared bimetallic nanodot-adenovirus chimera is small and uniform in particle size, and is beneficial to enrichment in tumor tissues through permeation and retention enhancement (EPR) effects; the drug loading capacity is high, the safety is good, and a high-intensity MRI signal can be generated at a tumor part. The bimetal nanodot-adenovirus chimera designed by the invention realizes the integration of diagnosis and treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug delivery carriers, and specifically relates to a bimetallic nanodot-oncolytic virus intravenous delivery system and a preparation method thereof and an application thereof in tumor immunotherapy. Background Art

[0002] Over the years, the incidence of cancer has continued to rise, becoming one of the leading causes of death worldwide. Traditionally, surgical resection, radiotherapy and chemotherapy are mainly used in clinical practice to treat tumors. In recent years, with the advancement and development of medicine, a variety of emerging treatment methods have emerged, such as photothermal, photodynamic and oncolytic virus therapy. As an emerging cancer treatment method that has attracted much attention, oncolytic virus therapy has unique advantages in its ability to selectively infect and kill tumor cells, and can specifically replicate and stimulate the body to produce anti-tumor immune responses. As a new force in the field of immunotherapy, oncolytic virus therapy has made significant progress after decades of development. However, the current clinical application of oncolytic viruses still has certain limitations, such as the administration method is mostly intratumoral injection, the use of oncolytic viruses alone has limited efficacy, and oncolytic virus therapy lacks a visual evaluation system.

[0003] Therefore, how to enhance the efficacy of oncolytic viruses and establish an evaluation system have become major scientific issues that need to be urgently addressed in the field of oncolytic virus therapy. Summary of the invention

[0004] In view of the above-mentioned defects in the prior art, the present invention designs and constructs a new intravenous delivery system based on bimetallic nanodots-oncolytic viruses. Bimetallic nanodots are albumin that simulates the process of chelating metal ions in organisms in nature. Albumin can trigger metal ions to form metal ion complexes under mild conditions, which exist in the cavity of the albumin skeleton and eventually form nanodots. This bimetallic nanodot not only does not change the original properties of albumin, but the metal nanodots formed at the same time can also play a corresponding role. Based on this, the present invention constructs iron and gadolinium bimetallic nanodots, and by covalently linking oncolytic adenoviruses, intravenous injection of oncolytic viruses is achieved to enhance the ability of oncolytic viruses to kill tumors and achieve magnetic resonance imaging.

[0005] The bimetallic nanodots are covalently linked to the oncolytic adenovirus so that the bimetallic nanodots are coated with the oncolytic adenovirus to shield the antigens on the surface of the oncolytic virus and avoid being cleared by the body's inherent immunity, thereby achieving the effect of long circulation in the body. At the same time, the bimetallic nanodots can enhance the tumor-killing ability of oncolytic viruses and can be used as contrast agents to achieve magnetic resonance imaging. Oncolytic viruses can activate the autophagy effect in cancer cells. The initiation of the autophagy effect provides support for the inner membrane structure required for viral replication, thereby increasing viral production. Autophagy can also enhance the iron-dependent cell death mode-ferroptosis. In the process of excessive autophagy, nuclear receptor coactivator 4 (NCOA4) is overexpressed, thereby promoting ferroptosis. It is worth noting that ferroptosis can trigger and amplify autophagy by producing reactive oxygen species (ROS), leading to autophagic cell death.

[0006] The present invention provides a new solution strategy for enhancing the efficacy of oncolytic adenovirus therapy. The present invention will provide a scientific basis for expanding the design of new, efficient and low-toxic microbial delivery systems and has important research value.

[0007] The present invention achieves the above object through the following technical solutions:

[0008] In the first aspect, the bimetallic nanodot-oncolytic virus intravenous delivery system (ie, bimetallic nanodot-adenovirus chimera) of the present invention is mainly realized by chemical bond cross-linking protein technology.

[0009] As an optional manner, the oncolytic virus is an oncolytic adenovirus; the bimetallic nanodots are iron nanodots and gadolinium nanodots generated inside bovine serum albumin; and the metal ions are selected from gadolinium nitrate and ferric chloride.

[0010] As an optional method, the bimetallic nanodots are covalently linked to the oncolytic virus via 4-maleimidobutyric acid-N-succinimide ester.

[0011] Among them, the mass ratio of oncolytic adenovirus to total protein of bimetallic nanodots is 1:2 to 1:20, and in a preferred embodiment is 1:20; the mass ratio of iron metal ions added in the biomimetic mineralization process to total protein is 50:1 to 1:1, and in a preferred embodiment is 46:1, and the mass ratio of gadolinium metal ions added in the biomimetic mineralization process to total protein is 50:1 to 1:1, and in a preferred embodiment is 36:1.

[0012] In a second aspect, the dual metal nanodot-oncolytic adenovirus intravenous delivery system (i.e., dual metal nanodot-adenovirus chimera) of the present invention is prepared by the following method:

[0013] The preparation method of the bimetallic nanodot-oncolytic virus intravenous delivery system of the present invention comprises the following steps:

[0014] (1) Construction and confirmation of bimetallic nanodots:

[0015] ① Add gadolinium nitrate and ferric chloride solution to the bovine serum albumin aqueous solution and mix under vigorous stirring;

[0016] ② adjusting the pH of the mixture to 12 using a 2.0 M sodium hydroxide solution, and then continuing to stir the mixture at 37° C. for 12 hours to form a crude product containing gadolinium and iron bimetallic nanodots (Gd / Fe-ND);

[0017] ③ Use a 100 kDa ultrafiltration concentration tube to centrifuge the crude product at 3000 rpm for 5 min to obtain the product;

[0018] ④ The product was dialyzed against distilled water for 24 hours to obtain the final product Gd / Fe-ND;

[0019] ⑤ Use dynamic light scattering, transmission electron microscopy, elemental analysis, circular dichroism and other methods to verify the particle size, potential and morphology of the final product Gd / Fe-ND;

[0020] (2) Construction and confirmation of bimetallic nanodot-oncolytic virus:

[0021] ① Take an appropriate amount of 4-maleimidobutyric acid-N-succinimide ester and dissolve it in dimethyl sulfoxide (DMSO);

[0022] ② diluting the solution prepared in step ① with an appropriate amount of phosphate buffer, adding excess Gd / Fe-ND, and incubating for 30 minutes;

[0023] ③ Use a 30kDa ultrafiltration concentration tube to centrifuge the mixture to the original volume;

[0024] ④ Add the concentrated solution to the oncolytic adenovirus solution pre-diluted in an appropriate amount of phosphate buffer and incubate again for 30 minutes;

[0025] ⑤ Dynamic light scattering, transmission electron microscopy and other methods were used to verify the particle size, potential and morphology of the bimetallic nanodots-oncolytic virus.

[0026] In the step (1)①, the specific operation is as follows: 2.0 mL of 20.0 mM gadolinium nitrate and 2.0 mL of 20.0 mM ferric chloride solution are added to 10.0 mL of 50.0 mg / mL bovine serum albumin aqueous solution, and mixed under vigorous stirring.

[0027] As an optional method, in step (2) ②, the specific operation is as follows: dilute the solution with an appropriate amount of phosphate buffer solution at pH 8, add an excess of Gd / Fe-ND, and incubate for 30 minutes.

[0028] As an optional method, in step (2)④, the specific operation is as follows: the concentrated solution is added to the oncolytic adenovirus solution pre-diluted in an appropriate amount of phosphate buffer pH 6.5, and incubated again for 30 minutes.

[0029] In a preferred embodiment, the preparation method of the bimetallic nanodot-oncolytic virus intravenous delivery system of the present invention comprises the following steps:

[0030] (1) Construction and confirmation of bimetallic nanodots:

[0031] ① Add 2.0 mL of 20.0 mM gadolinium nitrate and 2.0 mL of 20.0 mM ferric chloride solution to 10.0 mL of 50.0 mg / mL bovine serum albumin aqueous solution, and mix under vigorous stirring;

[0032] ② Using 2.0 M sodium hydroxide solution to adjust the pH value of the mixture to 12, and then continue to stir the mixture at 37° C. for 12 hours to form a crude product of gadolinium and iron bimetallic nanodots (Gd / Fe-ND);

[0033] ③ Use a 100 kDa ultrafiltration concentration tube to centrifuge the mixture at a speed of 3000 rpm / min for 5 min to obtain the product;

[0034] ④ The product was dialyzed with distilled water for 24 hours to obtain the final product Gd / Fe-ND;

[0035] ⑤ Use dynamic light scattering, transmission electron microscopy and other methods to characterize the particle size, potential and morphology of the final product Gd / Fe-ND;

[0036] (2) Construction and confirmation of dual metal nanodot-adenovirus chimera:

[0037] ① Take an appropriate amount of 4-maleimidobutyric acid-N-succinimide ester and dissolve it in dimethyl sulfoxide (DMSO);

[0038] ② Dilute the solution with an appropriate amount of phosphate buffer (pH 8), add excess Gd / Fe-ND, and incubate for 30 minutes;

[0039] ③ Use a 30kDa ultrafiltration concentration tube to centrifuge the mixture to the original volume;

[0040] ④ Add the concentrated solution to the oncolytic adenovirus solution pre-diluted in an appropriate amount of phosphate buffer (pH 6.5) and incubate again for 30 minutes;

[0041] ⑤ Dynamic light scattering, transmission electron microscopy and other methods were used to characterize the particle size, potential and morphology of the chimera.

[0042] In a third aspect, the present invention provides an application of the bimetallic nanodot-oncolytic virus intravenous delivery system described in the first aspect in a drug delivery system.

[0043] In a fourth aspect, the present invention provides the use of the bimetallic nanodot-oncolytic virus intravenous delivery system described in the first aspect in the preparation of anti-tumor drugs.

[0044] In a fifth aspect, the present invention provides the use of the bimetallic nanodot-oncolytic virus intravenous delivery system described in the first aspect in the preparation of a drug delivery system for injection, oral administration or local administration.

[0045] The present invention has the following beneficial effects:

[0046] (1) The present invention uses oncolytic adenovirus and gadolinium iron bimetallic nanodots as raw materials and utilizes the covalent force of 4-maleimidobutyric acid-N-succinimidyl ester to construct a bimetallic nanodot-adenovirus chimera, and evaluates the preparation performance, cytotoxicity, mechanism of action, in vivo antitumor effect, antitumor immunity, and anti-tumor recurrence and metastasis effects of the chimera.

[0047] The preparation process of the present invention is simple, and the prepared bimetallic nanodot-adenovirus chimera has a small and uniform particle size, which is conducive to enrichment in tumor tissue through the enhanced permeability and retention (EPR) effect; it has a high drug loading capacity and good safety, and can generate high-intensity MRI signals at the tumor site.

[0048] The bimetallic nanodot-adenovirus chimera designed by the present invention realizes the integration of tumor diagnosis and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 This is the DNTB result of the bimetallic nanodots (Gd / Fe-ND) in Example 1 of the present invention.

[0050] Figure 2 This is the circular dichroism result of the bimetallic nanodots (Gd / Fe-ND) in Example 1 of the present invention.

[0051] Figure 3 Elemental analysis results of the bimetallic nanodots (Gd / Fe-ND) in Example 1 of the present invention.

[0052] Figure 4 This is a particle size diagram of the dual metal nanodot-adenovirus chimera in Example 2 of the present invention.

[0053] Figure 5 This is the potential diagram of the double metal nanodot-adenovirus chimera in Example 2 of the present invention.

[0054] Figure 6 This is a transmission electron microscopy image of the double metal nanodot-adenovirus chimera in Example 2 of the present invention.

[0055] Figure 7 This is a confocal image of the double metal nanodot-adenovirus chimera in Example 2 of the present invention.

[0056] Figure 8 This is an MRI image of the double metal nanodot-adenovirus chimera in Example 2 of the present invention.

[0057] Fig. 9 This is a confocal image of the composite microorganism inducing cancer cells to produce ROS at the cellular level in Example 3 of the present invention.

[0058] Fig.10 This is a confocal image of the autophagosome in Example 4 of the present invention, in which the dual metal nanodot-adenovirus chimera induces autophagy of cancer cells at the cellular level.

[0059] Fig.11 This is a graph evaluating the ability of the dual metal nanodot-adenovirus chimera in inducing ferrous ion accumulation in cancer cells at the cellular level in Example 5 of the present invention.

[0060] Fig.12 This is an in vitro evaluation diagram of the dual metal nanodot-adenovirus chimera in Example 6 of the present invention promoting the replication of oncolytic adenovirus.

[0061] Fig.13 This is a diagram for the in vitro cytotoxicity evaluation of the dual-metal nanodot-adenovirus chimera in Example 7 of the present invention.

[0062] Fig.14 This is a diagram evaluating the distribution of the dual-metal nanodot-adenovirus chimera in body tissues after injection in Example 8 of the present invention.

[0063] Fig.15 This is an evaluation of the in vivo tissue distribution of the oncolytic adenovirus after injection of the dual-metal nanodot-adenovirus chimera in Example 9 of the present invention.

[0064] Fig.16 This is an MRI image of the tumor site after the injection of the dual metal nanodot-adenovirus chimera in Example 10 of the present invention.

[0065] Fig.17 This is a WB evaluation diagram of ferroptosis, autophagy, and autophagy-dependent ferroptosis produced in the tumor of the dual-metal nanodot-adenovirus chimera in Example 11 of the present invention.

[0066] Fig.18 This is a diagram for evaluating the replication of oncolytic adenovirus in a tumor of the dual-metal nanodot-adenovirus chimera in Example 11 of the present invention.

[0067] Fig.19 This is an immunofluorescence evaluation diagram of the tumor autophagy protein P62 of the dual-metal nanodot-adenovirus chimera in Example 11 of the present invention.

[0068] Fig. 20 This is a diagram showing the in vivo anti-tumor effect of the dual metal nanodot-adenovirus chimera in Example 12 of the present invention.

[0069] Fig.21 This is a diagram for the in vivo integrity evaluation of the dual metal nanodot-adenovirus chimera in Example 12 of the present invention.

[0070] Fig. 22 This is a diagram of the in vivo immunological investigation of the dual metal nanodot-adenovirus chimera in Example 13 of the present invention (G1: PBS, G2: Ad, G3: 3-MA+Ad@Gd / Fe-ND, G4: Gd / Fe-ND, G5: Ad@BSA, G6: Ad@Gd / Fe-ND);

[0071] Fig.23 The graph of the tumor growth curve of the dual metal nanodot-adenovirus chimera against recurrent tumors in vivo in Example 14 of the present invention (G1: PBS, G2: Ad, G3: 3-MA+Ad@Gd / Fe-ND, G4: Gd / Fe-ND, G5: Ad@BSA, G6: Ad@Gd / Fe-ND);

[0072] Fig.24 Figures before and after surgery of the dual metal nanodot-adenovirus chimera against recurrent tumors in vivo in Example 14 of the present invention (G1: PBS, G2: Ad, G3: 3-MA+Ad@Gd / Fe-ND, G4: Gd / Fe-ND, G5: Ad@BSA, G6: Ad@Gd / Fe-ND);

[0073] Fig.25 The graph of the tumor growth curve of the anti-metastatic tumor of the dual metal nanodot-adenovirus chimera in vivo in Example 14 of the present invention (G1: PBS, G2: Ad, G3: 3-MA+Ad@Gd / Fe-ND, G4: Gd / Fe-ND, G5: Ad@BSA, G6: Ad@Gd / Fe-ND);

[0074] Fig.26 These are the in vivo tumor imaging images of the dual metal nanodot-adenovirus chimera against metastatic tumors in vivo in Example 14 of the present invention (G1: PBS, G2: Ad, G3: 3-MA+Ad@Gd / Fe-ND, G4: Gd / Fe-ND, G5: Ad@BSA, G6: Ad@Gd / Fe-ND). DETAILED DESCRIPTION

[0075] The above contents of the present invention are further described in detail through the following specific examples, but the examples do not limit the present invention.

[0076] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0077] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0078] Example 1: Preparation and characterization of bimetallic nanodots

[0079] To prepare bimetallic nanodots (Gd / Fe-ND), 2.0 mL of 20.0 mM gadolinium nitrate and 2.0 mL of 20.0 mM ferric chloride solution were added to 10.0 mL of 50.0 mg / mL bovine serum albumin aqueous solution and mixed under vigorous stirring. The pH value of the mixture was adjusted to 12 using a 2.0 M sodium hydroxide solution. Then, the mixture was stirred for 12 hours at 37 ° C to form Gd / Fe-ND. Subsequently, the mixture was centrifuged using a 100 kDa ultrafiltration concentration tube, and the product was dialyzed with distilled water for 24 hours to finally obtain Gd / Fe-ND. The structure and composition of the bimetallic nanodots were verified by DTNB method, circular dichroism spectroscopy and elemental analysis, and the results are as shown Figure 1 , Figure 2 and Figure 3 shown.

[0080] Example 2: Preparation and characterization of dual metal nanodot-adenovirus chimeras

[0081] The bimetallic nanodot-oncolytic virus chimera (Ad@Gd / Fe-ND) was prepared, and 4-maleimidobutyric acid-N-succinimide ester was used to connect Gd / Fe-ND to Ad. Maleimide and thiol formed a stable thioether bond under mild conditions (pH 6.5-7.5), and succinimide reacted with primary amine under slightly alkaline conditions (pH 7.2-9) to produce a stable amide bond. Gd / Fe-ND or Ad can be selectively connected by adjusting the pH value of the solution, succinimide is connected to Gd / Fe-ND, and maleimide is connected to Ad.

[0082] First, take an appropriate amount of 4-maleimidobutyric acid-N-succinimide ester and dissolve it in dimethyl sulfoxide (DMSO), dilute the solution with an appropriate amount of PBS (pH 8), and add an excess of Gd / Fe-ND for 30 minutes of incubation. Subsequently, use an ultrafiltration concentration tube to centrifuge the mixture to the original volume, add the concentrated solution to the Ad solution previously diluted in an appropriate amount of PBS (pH 6.5), and incubate again for 30 minutes. Finally, concentrate the mixture to the required volume. The successful preparation of the bimetallic nanodot-adenovirus chimera was demonstrated by particle size, potential, electron microscopy and confocal imaging. The results are shown in Figure 2. Figure 4 , Figure 5 , Figure 6 , Figure 7 In addition, the imaging capability of the dual metal nanodot-adenovirus chimera was demonstrated by MRI experiments. Figure 8 shown.

[0083] Example 3: Evaluation of the ability of the bimetallic nanodot-adenovirus chimera to induce ROS generation at the cellular level

[0084] Non-small cell lung cancer cells (TC-1) were cultured in a 12-well cell culture plate. After the cells grew to 80% confluence, the culture medium was discarded and the cells were rinsed twice with PBS. An appropriate volume of blank culture medium working solution containing 10 μM DCFH-DA fluorescent dye was added, and the cells were incubated in a 37°C cell culture incubator in the dark for 1 hour. The DCFH-DA fluorescent dye working solution was discarded and the cells were rinsed twice with PBS. The culture medium dispersion containing PBS, Ad, and Ad@Gd / Fe-ND were added to each group, and the cells were incubated in the dark at 37°C for 3 hours. The drug solution was discarded, and the cells were rinsed twice with PBS. After the cells were digested, an appropriate amount of cell staining buffer was added to resuspend the cells. The fluorescence intensity of each group was photographed by fluorescence confocal microscopy to evaluate the ability of the composite organism to induce cells to produce ROS. Fig. 9 As shown, both the confocal and flow cytometry results showed that the bimetallic nanodot-adenovirus chimera could increase the level of ROS at the cellular level in vitro.

[0085] Example 4: Evaluation of the ability of bimetallic nanodot-adenovirus chimeras to induce autophagy in cancer cells at the cellular level

[0086] TC-1 cells (1×10 5 The cells were cultured in a cell culture incubator for 24 hours to allow the cells to adhere to the wall and grow. Then, the culture medium was aspirated with a pipette and PBS, Ad (10 7 pfu) and Ads@Gd / Fe-ND (10 7pfu) of culture medium, and then place it in a cell culture incubator for incubation for 24 or 48 hours. After incubation, aspirate the culture medium, add 1mL of MDC staining solution to each well, and incubate in a cell culture incubator at 37°C in the dark for 30min. Aspirate the MDC staining solution, wash three times with assay buffer, and use 1mL of assay buffer each time. Aspirate the assay buffer, and then add 1mL of assay buffer. Then add EB staining solution for staining. After incubation for 10min, wash the cells three times with serum-free cell culture medium to fully remove the EB staining solution that has not entered the cells, and place them under CLSM for photography to examine the production of autophagosomes in the cells. The level of autophagosomes in the Ad@Gd / Fe-ND group was significantly higher than that in the PBS group and the Ad group, indicating that Ad@Gd / Fe-ND has a higher level of autophagy. The results are shown in Fig.10 shown.

[0087] Example 5: Evaluation of the ability of the dual metal nanodot-adenovirus chimera to induce ferrous ion accumulation in cancer cells at the cellular level

[0088] TC-1 cells (1×10 5 The cells were cultured in a cell culture incubator for 24 hours to allow the cells to adhere to the wall and grow. Subsequently, the culture medium was aspirated with a pipette and PBS, Gd / Fe-ND and Ad@Gd / Fe-ND (10 7 pfu) of culture medium, and then placed in a cell culture incubator for 24 or 48 hours, the culture medium was removed, and 1 μmol / L FerroOrange working solution was added to each well for staining. Incubate for 30 minutes, then add DAPI working solution for 10 minutes, and then wash the cells three times with serum-free cell culture medium to fully remove FerroOrange and DAPI that have not entered the cells, and place them under CLSM for photography to examine Fe 2+ At the intracellular level, compared with the PBS group and the Ad group, the intracellular ferrous ion level in the Ad@Gd / Fe-ND group was higher, indicating that the level of ferroptosis in the Ad@Gd / Fe-ND group was higher. Fig.11 shown.

[0089] Example 6: In vitro evaluation of the dual metal nanodot-adenovirus chimera in promoting Ad replication

[0090] TC-1 cells were inoculated in a cell culture plate. When the cells grew to occupy 80% of the bottom, the culture medium was aspirated with a 2mL syringe and the cells were washed twice with PBS. Then, different concentrations of Ad@Gd / Fe-ND were added to each group, namely 5pfu / cell, 10pfu / cell, 50pfu / cell and 100pfu / cell, and the wells were incubated at 37°C for different times. After the incubation, the solution was aspirated and the cells were rinsed twice with PBS. Then, an equal amount of fresh culture medium was added and the culture plate was placed at -80°C for 3 freeze-thaw cycles. Subsequently, the freeze-thaw solution was collected and centrifuged at 840×g for 30 minutes at 4°C. The supernatant was collected and 1% volume of Triton was added. Then, the pre-denaturation treatment was performed at 98°C and the denatured proteins were removed by centrifugation at 3600×g for 10 minutes. Finally, the supernatant was collected and quantitatively detected by RT-qPCR. Ad@Gd / Fe-ND at a concentration of 50pfu / cell showed a good ability to enhance viral replication. The ability of Ad@Gd / Fe-ND to enhance replication was poor at 100pfu / cell, probably because too high a concentration of Ad would cause rapid cell death and the virus had not yet replicated in large quantities, so the quantitative level was low. 5pfu / cell and 10pfu / cell had poor enhancement effects within the specified time due to their low concentrations. Fig.12 shown.

[0091] Example 7: In vitro cytotoxicity evaluation of dual metal nanodot-adenovirus chimeras

[0092] Take cells with good growth status, digest and centrifuge them, discard the upper culture medium, resuspend the cells with 1mL culture medium, take 10μL of cell suspension and add it to the cell counting plate, and count under a microscope. Dilute the cell suspension density to 1×10 4Cells / mL were inoculated into 96-well plates, and 100 to 150 μL of cell suspension was added to each well. After culturing in an incubator, the old culture medium was discarded after the cells were completely attached to the wall. PBS, BSA, Ad, Gd / Fe-ND, Ad@Gd / Fe-ND, 3-MA (3-methyladenine) + BSA, 3-MA+Ad, 3-MA+Gd / Fe-ND and 3-MA+Ad@Gd / Fe-ND solutions prepared with serum-free culture medium were added, 150 μL per well. Three parallel wells were set for each group, and the zeroing well was a well without cells. An equal amount of cell culture medium was added to the zeroing well. After culturing for 24h and 48h, 50 μL of MTT solution was added to each well under light-proof conditions, and the culture was continued for 4h. Then the culture medium was discarded, 150 μL of DMSO solution was added, and the well was placed on an oscillator for 10min. The absorbance value of each well was measured by a microplate reader at a wavelength of 490nm, and the corresponding cell survival percentage was obtained by calculation. The comparison between the BSA group and the 3-MA+BSA group showed that a certain amount of 3-MA was not cytotoxic. Therefore, 3-MA can be used as an autophagy inhibitor in subsequent different dosing groups. Compared with the Ad group, the addition of 3-MA will weaken the cytotoxicity of Ad by inhibiting autophagy, indicating that autophagy plays a key role in oncolytic viruses killing tumor cells. Compared with the Gd / Fe-ND group and the Ad@Gd / Fe-ND group, Ad@Gd / Fe-ND showed more significant cytotoxicity. The results are as follows Fig.13 shown.

[0093] Example 8: Evaluation of in vivo tissue distribution after injection of dual metal nanodot-adenovirus chimeras

[0094] When the tumor grows to about 200-300 mm 3 At the time of the study, lung cancer (LUC-TC-1) tumor-bearing C57BL / 6 mice were randomly divided into two groups, with 3 mice in each group. D-luciferin potassium salt solution, which is the most commonly used firefly luciferase substrate, was injected. In the presence of substances such as ATP, D-luciferin potassium salt emits fluorescence with a wavelength of about 560nm through an enzyme-catalyzed reaction. In vivo imaging of TC-1 tumors with their own LUC was performed using D-luciferin potassium salt. Subsequently, Ad@Gd / Fe-ND and Ad pre-stained with CY7-NHS were injected through the tail vein, where the equivalent concentration of Ad was 10 7pfu. In vivo imaging was performed 6 hours, 12 hours, and 24 hours after administration. After the last imaging, the mice were killed, and the heart, liver, spleen, lungs, kidneys, and tumors were removed. The surface of each tissue was rinsed clean, and the ex vivo tissue was imaged. Within 24 hours after intravenous administration, Ad@Gd / Fe-ND showed a stronger CY7 signal overlapping with tumor fluorescence than Ad, indicating that Ad@Gd / Fe-ND has a stronger tumor targeting and accumulation ability. Specific analysis showed that within 6 hours after administration, the accumulation of Ad@Gd / Fe-ND in the tumor was the highest, while after 12 and 24 hours, the fluorescence intensity at the tumor site gradually weakened. This shows that Ad@Gd / Fe-ND can better target the tumor site. Next, we studied the drug accumulation in ex vivo organs. In contrast, 24 hours after administration, the Ad@Gd / Fe-ND group still showed higher tumor accumulation, while the Ad group had higher accumulation in the liver. The results are shown in Fig.14 shown.

[0095] Example 9: Evaluation of Ad tissue distribution in vivo after injection of dual metal nanodot-adenovirus chimera

[0096] When the tumor volume grows to about 200-300mm 3 The mice were randomly divided into two groups, with 3 mice in each group. Ad@Gd / Fe-ND and Ad were injected through the tail vein, with the equivalent concentration of Ad being 10 7 pfu. The mice were killed 6 hours after administration, and the heart, liver, spleen, lungs, kidneys and tumors were quickly removed. The surface of each tissue was rinsed with physiological saline and dried with filter paper. About 200 mg of each tissue sample was cut and accurately weighed. The samples were placed in a 10 mL EP tube and chopped up. DNA was extracted using a tissue DNA extraction kit, and Ad was quantified using RT-qPCR. In the quantification of liver tissue, the amount of Ad in the Ad group was about 4 times that of the Ad@Gd / Fe-ND group. In tumor tissue, the amount of Ad in the Ad@Gd / Fe-ND group was about 5 times that of the Ad group. The results are as follows Fig.15 shown.

[0097] Example 10: MRI of the tumor site after injection of dual metal nanodot-adenovirus chimera

[0098] When the tumor volume grows to about 200-300mm 3 At 4 pm, Ad@Gd / Fe-ND and PBS were injected into the tail vein, with Ad equivalent concentration of 10 7pfu. At 0h, 4h and 12h after administration, the mice were anesthetized with isoflurane and subjected to magnetic resonance imaging. At 0h after administration, there was no significant difference in tumor imaging between the two groups. Compared with the PBS group, the tumor MRI of the Ad@Gd / Fe-ND group showed a brighter trend 4h after administration. 6h after injection, the tumor tissue of the Ad@Gd / Fe-ND group had a more obvious boundary with other tissues, which could more intuitively judge the tumor size. Fig.16 shown.

[0099] Example 11: Evaluation of the mechanism of action of the dual metal nanodot-adenovirus chimera in tumors

[0100] A TC-1 ectopic tumor-bearing mouse model was constructed and divided into the following groups: PBS group, Ad group, 3-MA+Ad@Gd / Fe-ND group, Gd / Fe-ND group, Ad@BSA group and Ad@Gd / Fe-ND group. After 72 hours, the mice were dissected to remove the tumor tissues. The obtained tumor tissues were subjected to in vivo western blot experiments of LC3 autophagy protein, GPX4 ferroptosis protein and autophagy-dependent ferroptosis NCOA4 protein, P62 autophagy protein immunofluorescence sections, and H&E sections of tumor tissues. At the same time, an appropriate amount of tumor tissue was taken and placed in an EP tube, cut into pieces, and homogenized. Take 150 μL of the homogenate, separate and purify the DNA according to the steps of the DNA separation and extraction kit, and detect it using a real-time PCR instrument. Fig.17 , Fig.18 and Fig.19 As shown, the results indicate that the bimetallic nanodot-adenovirus chimera can promote the production of ROS in the tumor, induce tumor cell autophagy, excessive autophagy enhances ferroptosis, and enhance the replication of Ad in the tumor after tail injection.

[0101] Example 12: In vivo anti-tumor efficacy and safety evaluation of dual metal nanodot-adenovirus chimeras

[0102] The TC-1 ectopic tumor-bearing mouse model was established and the tumor volume grew to about 250 mm 3 The tumor-bearing mice were randomly divided into six groups: PBS group, Ad group, 3-MA+Ad@Gd / Fe-ND group, Gd / Fe-ND group, Ad@BSA group and Ad@Gd / Fe-ND group. PBS, Ad, 3-MA (intraperitoneal injection)+Ad@Gd / Fe-ND, Gd / Fe-ND, Ad@BSA and Ad@Gd / Fe-ND were injected through the tail vein, respectively. The equivalent concentration of Ad was 10 7 pfu. The drug was injected into the tail vein every two days for a total of 4 times (on the 5th, 7th, 9th and 11th days after tumor implantation). The tumor volume and weight of the mice in the experimental group were measured and recorded every day from the first day after administration to monitor tumor growth. Fig. 20 , Fig.21 As shown, the results showed that compared with simple oncolytic viruses and bimetallic nanodots, the bimetallic nanodot-adenovirus chimera can exert better anti-tumor efficacy after tail injection, and no obvious safety issues were found.

[0103] Example 13: In vivo immunological evaluation of dual metal nanodot-adenovirus chimeras

[0104] Blood, tumor tissue, and spleen were collected from mice sacrificed after treatment in Example 12. Single cell suspension was prepared using collagenase IV, hyaluronidase, and deoxyribonuclease I. 100 μL, 1×10 7 Each sample was incubated with relevant antibodies and the antibody content was determined by flow cytometry. Fig. 22 As shown, the results indicate that compared with simple oncolytic viruses and bimetallic nanodots, the bimetallic nanodot-adenovirus chimera has a better ability to reshape the suppressive immune microenvironment in the tumor after tail injection.

[0105] Example 14: In vivo pharmacodynamic evaluation of dual metal nanodot-adenovirus chimeras in anti-tumor recurrence and metastasis models

[0106] The anti-tumor immune effect of Ad@Gd / Fe-ND was evaluated by subcutaneously inoculating TC-1 cells in the left and right abdomen of mice to model tumor recurrence and metastasis. First, the anti-tumor recurrence ability of Ad@Gd / Fe-ND was analyzed, and the tumor curve was drawn by measuring the volume of the recurrent tumor. The results are shown in Fig.23 The postoperative tumor volume continued to grow in the PBS group, Ad group, 3-MA+Ad@Gd / Fe-ND group, and Gd / Fe-ND group, indicating that PBS, Ad, 3-MA+Ad@Gd / Fe-ND, and Gd / Fe-ND could not inhibit tumor growth and had little effect on recurrent tumors. Ad@BSA and Ad@Gd / Fe-ND could inhibit tumor growth, among which Ad@Gd / Fe-ND had the most obvious effect, controlling the tumor volume to 500mm 3 Pre-operative and post-operative photos Fig.24 Second, metastatic tumors were analyzed. The metastatic tumors were inoculated on the 16th day and measured on the 20th day. The tumor curve is shown in Fig.25 As shown in the figure, the 3-MA+Ad@Gd / Fe-ND group, the Gd / Fe-ND group, the Ad@BSA group and the Ad@Gd / Fe-ND group all had tumor inhibition effects, among which the Ad@Gd / Fe-ND group had the strongest tumor inhibition effect. Fig.26 shown.

[0107] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A dual-metal nanodot-oncolytic virus intravenous delivery system, Features: The system uses bimetallic nanodots as carriers to encapsulate oncolytic adenovirus; the mass ratio of oncolytic adenovirus to bimetallic nanodots total protein is 1:2 to 1:20; the mass ratio of iron metal ions added during the formation of bimetallic nanodots to albumin is 50:1 to 1:1, and the mass ratio of gadolinium metal ions to total protein is 50:1 to 1:

1.

2. The bimetallic nanodot-oncolytic virus intravenous delivery system according to claim 1, Features: The oncolytic virus is an oncolytic adenovirus; the bimetallic nanodots are nanodots formed by the combination of bovine serum albumin and metal ions inside the nanodots; the metal ions are selected from gadolinium nitrate and ferric chloride.

3. The bimetallic nanodot-oncolytic virus intravenous delivery system according to claim 1, Features: The bimetallic nanodots are covalently linked to the oncolytic virus via 4-maleimidobutyric acid-N-succinimide ester.

4. The preparation method of the bimetallic nanodot-oncolytic adenovirus intravenous delivery system according to any one of claims 1 to 3, Features: The following steps are involved: (1) Construction and confirmation of bimetallic nanodots: ① Add gadolinium nitrate and ferric chloride solution to the bovine serum albumin aqueous solution and mix under vigorous stirring; ② adjusting the pH value of the mixture to 12 using a 2.0 M sodium hydroxide solution, and then continuing to stir the mixture at 37° C. for 12 hours to form a crude product containing gadolinium and iron bimetallic nanodots (Gd / Fe-ND); ③ Use a 100 kDa ultrafiltration concentration tube to centrifuge the crude product at 3000 rpm for 5 min to obtain the product; ④ The product was dialyzed against distilled water for 24 hours to obtain the final product Gd / Fe-ND; ⑤ Dynamic light scattering, transmission electron microscopy, elemental analysis, and circular dichroism were used to verify the particle size, potential, and morphology of the final product Gd / Fe-ND; (2) Construction and confirmation of bimetallic nanodot-oncolytic virus chimera: ① Take an appropriate amount of 4-maleimidobutyric acid-N-succinimide ester and dissolve it in dimethyl sulfoxide (DMSO); ② diluting the solution prepared in step ① with an appropriate amount of phosphate buffer, adding excess Gd / Fe-ND, and incubating for 30 minutes; ③ Use a 30kDa ultrafiltration concentration tube to centrifuge the mixture to the original volume; ④ Add the concentrated solution to the oncolytic adenovirus solution pre-diluted in an appropriate amount of phosphate buffer and incubate again for 30 minutes; ⑤ Dynamic light scattering and transmission electron microscopy were used to verify the particle size, potential and morphology of the chimera.

5. The preparation method of the bimetallic nanodot-oncolytic virus intravenous delivery system according to claim 4, Features: In the step (1)①, the specific operation is as follows: 2.0 mL of 20.0 mM gadolinium nitrate and 2.0 mL of 20.0 mM ferric chloride solution are added to 10.0 mL of 50.0 mg / mL bovine serum albumin aqueous solution, and mixed under vigorous stirring.

6. The preparation method of the bimetallic nanodot-oncolytic virus intravenous delivery system according to claim 4, Features: In the step (2) ②, the specific operation is as follows: dilute the solution with an appropriate amount of phosphate buffer solution at pH 8, add an excess of Gd / Fe-ND, and incubate for 30 minutes.

7. The method for preparing the bimetallic nanodot-oncolytic virus intravenous delivery system according to claim 4, Features: In step (2)④, the specific operation is as follows: the concentrated solution is added to the oncolytic adenovirus solution pre-diluted in an appropriate amount of phosphate buffer pH 6.5, and incubated again for 30 minutes.

8. Use of the bimetallic nanodot-oncolytic virus intravenous delivery system according to any one of claims 1 to 3 in a drug delivery system.

9. Use of the bimetallic nanodot-oncolytic virus intravenous delivery system according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.

10. Use of the bimetallic nanodot-oncolytic virus intravenous delivery system according to any one of claims 1 to 3 in the preparation of a drug delivery system for injection, oral administration or local administration.

Citation Information

Patent Citations

  • Preparation method of double functional metal nano-cluster

    CN107441511A

  • Bovine serum albumin-ferrum nanometer compound and preparation method and application thereof

    CN110548017A

  • Oncolytic virus intravenous delivery system based on engineered bacterium outer membrane vesicles and construction method and application of oncolytic virus intravenous delivery system

    CN115252576A

  • Preparation and application of PEGylated albumin modified oncolytic virus intravenous delivery preparation

    CN115624524A

  • Preparation and anti-tumor application of erythrocyte-loaded oncolytic virus intravenous delivery preparation

    CN116196437A